Role of immunohistochemical markers in predicting progression of dysplasia to advanced neoplasia in patients with ulcerative colitis

Inflammatory Bowel Diseases

Volumn 18, Issue 3, 2012, Pages 480-488

  Van Schaik, Fiona D M ^a   Oldenburg, Bas ^a   Offerhaus, G Johan A ^a   Schipper, Marguerite E I ^a   Vleggaar, Frank P ^a   Siersema, Peter D ^a   Van Oijen, Martijn G H ^a   Ten Kate, Fiebo J W ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

immunohistochemistry; neoplasia; ulcerative colitis

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; ALDEHYDE DEHYDROGENASE; BETA CATENIN; CYCLIN D1; HERMES ANTIGEN; KI 67 ANTIGEN; PROTEIN P21; PROTEIN P53;

ADULT; ADVANCED CANCER; ARTICLE; CLINICAL ARTICLE; COLON BIOPSY; CONTROLLED STUDY; DISEASE COURSE; DYSPLASIA; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INDEFINITE DYSPLASIA; LOW GRADE DYSPLASIA; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; ALDEHYDE DEHYDROGENASE; ANTIGENS, CD44; BETA CATENIN; BIOLOGICAL MARKERS; CELL TRANSFORMATION, NEOPLASTIC; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RACEMASES AND EPIMERASES; STATISTICS, NONPARAMETRIC; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84857368717     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21722     Document Type: Article

References (36)

1. Itzkowitz SH, Yio X,. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol. 2004; 287: G7-17. (Pubitemid 38802113)
2. Befrits R, Ljung T, Jaramillo E, et al. Low-grade dysplasia in extensive, long-standing inflammatory bowel disease: a follow-up study. Dis Colon Rectum. 2002; 45: 615-620. (Pubitemid 34507236)
3. Connell WR, Lennard-Jones JE, Williams CB, et al. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology. 1994; 107: 934-944. (Pubitemid 24294554)
4. Jess T, Loftus EV Jr, Velayos FS, et al. Incidence and prognosis of colorectal dysplasia in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Inflamm Bowel Dis. 2006; 12: 669-676. (Pubitemid 44253749)
5. Ullman T, Croog V, Harpaz N, et al. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology. 2003; 125: 1311-1319. (Pubitemid 37409751)
6. Rutter MD, Saunders BP, Wilkinson KH, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology. 2006; 130: 1030-1038.
7. Ullman T, Croog V, Harpaz N, et al. Progression to colorectal neoplasia in ulcerative colitis: effect of mesalamine. Clin Gastroenterol Hepatol. 2008; 6: 1225-1230.
8. Pekow JR, Hetzel JT, Rothe JA, et al. Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis. Inflamm Bowel Dis. 2010; 16: 1352-1356.
9. Lashner BA, Shapiro BD, Husain A, et al. Evaluation of the usefulness of testing for p53 mutations in colorectal cancer surveillance for ulcerative colitis. Am J Gastroenterol. 1999; 94: 456-462. (Pubitemid 29084669)
10. Sato A, MacHinami R,. p53 immunohistochemistry of ulcerative colitis-associated with dysplasia and carcinoma. Pathol Int. 1999; 49: 858-868.
11. Harpaz N, Peck AL, Yin J, et al. p53 protein expression in ulcerative colitis-associated colorectal dysplasia and carcinoma. Hum Pathol. 1994; 25: 1069-1074.
12. Wong NA, Mayer NJ, MacKell S, et al. Immunohistochemical assessment of Ki67 and p53 expression assists the diagnosis and grading of ulcerative colitis-related dysplasia. Histopathology. 2000; 37: 108-114. (Pubitemid 30608507)
13. Michalides RJ,. Cell cycle regulators: mechanisms and their role in aetiology, prognosis, and treatment of cancer. J Clin Pathol. 1999; 52: 555-568. (Pubitemid 29371899)
14. Ioachim EE, Katsanos KH, Michael MC, et al. Immunohistochemical expression of cyclin D1, cyclin E, p21/waf1 and p27/kip1 in inflammatory bowel disease: correlation with other cell-cycle-related proteins (Rb, p53, ki-67 and PCNA) and clinicopathological features. Int J Colorectal Dis. 2004; 19: 325-333. (Pubitemid 38868298)
15. van DH, Wink JC, Vissers KJ, et al. Wnt pathway-related gene expression during malignant progression in ulcerative colitis. Acta Histochem. 2007; 109: 266-272. (Pubitemid 46962077)
16. Wong NA, Mayer NJ, Anderson CE, et al. Cyclin D1 and p21 in ulcerative colitis-related inflammation and epithelial neoplasia: a study of aberrant expression and underlying mechanisms. Hum Pathol. 2003; 34: 580-588. (Pubitemid 36750370)
17. Kolligs FT, Bommer G, Goke B,. Wnt/beta-catenin/tcf signaling: a critical pathway in gastrointestinal tumorigenesis. Digestion. 2002; 66: 131-144. (Pubitemid 36091845)
18. Aust DE, Terdiman JP, Willenbucher RF, et al. Altered distribution of beta-catenin, and its binding proteins E-cadherin and APC, in ulcerative colitis-related colorectal cancers. Mod Pathol. 2001; 14: 29-39. (Pubitemid 32098808)
19. Mikami T, Mitomi H, Hara A, et al. Decreased expression of CD44, alpha-catenin, and deleted colon carcinoma and altered expression of beta-catenin in ulcerative colitis-associated dysplasia and carcinoma, as compared with sporadic colon neoplasms. Cancer. 2000; 89: 733-740. (Pubitemid 30658570)
20. Andersen SN, Rognum TO, Bakka A, et al. Ki-67: a useful marker for the evaluation of dysplasia in ulcerative colitis. Mol Pathol. 1998; 51: 327-332. (Pubitemid 29003269)
21. Shinozaki M, Watanabe T, Kubota Y, et al. High proliferative activity is associated with dysplasia in ulcerative colitis. Dis Colon Rectum. 2000; 43 (10 suppl): S34-S39.
22. Sjoqvist U, Ost A, Lofberg R,. Increased expression of proliferative Ki-67 nuclear antigen is correlated with dysplastic colorectal epithelium in ulcerative colitis. Int J Colorectal Dis. 1999; 14: 107-113. (Pubitemid 29295193)
23. Noffsinger AE, Miller MA, Cusi MV, et al. The pattern of cell proliferation in neoplastic and nonneoplastic lesions of ulcerative colitis. Cancer. 1996; 78: 2307-2312. (Pubitemid 26392828)
24. Claessen MM, Schipper ME, Oldenburg B, et al. WNT-pathway activation in IBD-associated colorectal carcinogenesis: potential biomarkers for colonic surveillance. Cell Oncol. 2010; 32: 303-310.
25. Farraye FA, Odze RD, Eaden J, et al. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010; 138: 746-774, 774.
26. van Schaik FD, Ten Kate FJ, Offerhaus GJ, et al. Misclassification of dysplasia in patients with inflammatory bowel disease: Consequences for progression rates to advanced neoplasia. Inflamm Bowel Dis. [Epub ahead of print] doi: 10.1002/ibd.21467.
27. Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol. 1983; 14: 931-968.
28. van Diest PJ,. No consent should be needed for using leftover body material for scientific purposes. BMJ. 2002; 325: 648-651.
29. Luo J, Zha S, Gage WR, et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res. 2002; 62: 2220-2226. (Pubitemid 34411693)
30. Rubin MA, Zhou M, Dhanasekaran SM, et al. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA. 2002; 287: 1662-1670. (Pubitemid 34289218)
31. Dorer R, Odze RD,. AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease. Am J Surg Pathol. 2006; 30: 871-877. (Pubitemid 44264978)
32. Marx A, Wandrey T, Simon P, et al. Combined alpha-methylacyl coenzyme A racemase/p53 analysis to identify dysplasia in inflammatory bowel disease. Hum Pathol. 2009; 40: 166-173.
33. Harris CC, Hollstein M,. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med. 1993; 329: 1318-1327. (Pubitemid 23317333)
34. Hollstein M, Sidransky D, Vogelstein B, et al. p53 mutations in human cancers. Science. 1991; 253: 49-53. (Pubitemid 21917115)
35. Carpentino JE, Hynes MJ, Appelman HD, et al. Aldehyde dehydrogenase-expressing colon stem cells contribute to tumorigenesis in the transition from colitis to cancer. Cancer Res. 2009; 69: 8208-8215.
36. Nathanson JW, Yadron NE, Farnan J, et al. p53 mutations are associated with dysplasia and progression of dysplasia in patients with Crohn's disease. Dig Dis Sci. 2008; 53: 474-480. (Pubitemid 351170026)